HOUSTON , March 23, 2026 /PRNewswire/ -- Intelligenome, a global leader in CRISPR-based in vitro diagnostic (IVD) technology, is pleased to announce that it has entered into a research and development subaward agreement with Cornell University to support the development of a rapid, low-cost, portable diagnostic solution for tuberculosis (TB). The project is part of an NIH-funded program focused on improving access to innovative technologies for human health. Under the agreement, Intelligenome will contribute its point-of-care testing (POCT) platform to a program centered on cell-free DNA (cfDNA) TB detection from respiratory and blood samples. The company's work will support advancement of a portable lab-in-tube assay designed to simplify testing and bring rapid, non-sputum based diagnosis closer to patients, particularly in settings where laboratory infrastructure may be limited. Full story available on Benzinga.com
Intelligenome Announces R&D Subaward Agreement with Cornell University to Advance Rapid Point-of-Care Tuberculosis Diagnosis
